Elliott F. Winton, MD
Professor, Hematology & Medical Oncology
Emory University School of Medicine
Co-Director, Myeloid Leukemia Program
Winship Cancer Institute of Emory University
Office: Winship Cancer Institute of Emory University
For all patient inquiries or appointment requests, please dial (404) 778-1900.
Dr. Elliott Winton received his MD at the University of Chicago in 1967, completed his specialty training and joined the faculty at Emory University School of Medicine in 1974. During his career on the Emory faculty, Dr. Winton's research has focused on understanding normal and malignant hematopoiesis at the bench and bedside. At the bedside he has conducted clinical trials to test the effects of novel therapies and improved supportive care for treating myeloid malignancies, collaborated in establishing the first hematopoietic stem cell transplantation program in Georgia, and conducted studies to improve understanding of several hematologic disease entities (e.g. discovery of hemoglobin Atlanta, studies on large granular lymphocytic leukemia, frequent occurrence of copper deficiency masquerading as myelodysplasia). Laboratory and animal-based projects included methods to better quantify in vitro and in vivo granulopoiesis, granulopoietic growth factor perturbations during murine marrow regeneration, and the development of preclinical models for studying newly introduced recombinant human hematopoietic growth factors using the rhesus macaque.
Dr. Winton's primary clinical research continues to be focused on improving therapy for patients with myeloid malignancies. In recent years he has specialized in the non-BCR/ABL myeloproliferative neoplasms (MPNs) (polycythemi rubra vera, essential thrombocythemia, myelofibrosis) as well as rare granulocytic neoplasias such as systemic mastocytosis and eosinophilia. In 2008, Dr. Winton secured Winship Cancer Institute membership in the Myeloproliferative Disorder Research Consortium (MPD-RC), an NIH sponsored group of international clinical and basic scientists dedicated to improved understanding of the basic pathophysiology of MPNs and to the introduction and study of novel therapies. Several MPD-RC clinical trials are opened or soon to open and are accruing patients. All these studies include a state of the art tissue banking program. In 2009-2010, Dr. Winton collaborated in the pivotal phase III trial of the first-in-class JAK-2 inhibitor (Ruxolitinib, Incyte Corporation).
- View publications on Pubmed
View clinical trials at Winship Cancer Institute